iShares Biotechnology ETF (NASDAQ:IBB) Shares Bought by Simon Quick Advisors LLC

Simon Quick Advisors LLC grew its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 93.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,886 shares of the financial services provider’s stock after buying an additional 913 shares during the quarter. Simon Quick Advisors LLC’s holdings in iShares Biotechnology ETF were worth $288,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new stake in iShares Biotechnology ETF in the third quarter valued at $64,365,000. Barclays PLC boosted its position in shares of iShares Biotechnology ETF by 25.9% in the 3rd quarter. Barclays PLC now owns 1,626,817 shares of the financial services provider’s stock valued at $263,024,000 after purchasing an additional 334,719 shares during the period. Royal Bank of Canada boosted its position in shares of iShares Biotechnology ETF by 28.3% in the 3rd quarter. Royal Bank of Canada now owns 1,328,604 shares of the financial services provider’s stock valued at $214,809,000 after purchasing an additional 293,379 shares during the period. Balyasny Asset Management LLC acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at $20,750,000. Finally, DeDora Capital Inc. acquired a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at $24,758,000. Institutional investors own 65.38% of the company’s stock.

Shares of NASDAQ:IBB traded down $2.40 during midday trading on Friday, reaching $116.65. The company had a trading volume of 4,313,426 shares, compared to its average volume of 2,439,756. iShares Biotechnology ETF has a 1-year low of $115.47 and a 1-year high of $177.37. The company has a fifty day simple moving average of $126.87 and a two-hundred day simple moving average of $139.78.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 30th. Shareholders of record on Friday, March 25th were issued a $0.118 dividend. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.04. This represents a $0.47 annualized dividend and a dividend yield of 0.40%. The ex-dividend date was Thursday, March 24th.

iShares Biotechnology ETF Company Profile (Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.